INCB161734

DRUG4 trials

Sponsors

Incyte Corp., Incyte Corporation

Conditions

Healthy ParticipantsPancreatic Ductal AdenocarcinomaSolid Tumors

Phase 1

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

RecruitingNCT06179160

Incyte CorporationSolid Tumors

Start: 2024-01-04End: 2027-01-01Target: 710Updated: 2026-05-04

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

CompletedNCT07018635

Incyte CorporationHealthy Participants

Start: 2025-07-16End: 2025-09-29Updated: 2025-11-26

Phase 3

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

RecruitingNCT07522073

Incyte CorporationSolid Tumors

Start: 2026-04-09End: 2029-03-19Target: 588Updated: 2026-07-20

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

Not yet recruitingCTIS2025-525009-18-00

Incyte Corp.Pancreatic Ductal Adenocarcinoma

Target: 71Updated: 2026-06-29

Related Papers

Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).

Journal of Clinical Oncology2026-01-10